Kaplan–Meier survival analysis showed that patients with lower expression of MIR200CHG had much worse overall survival (hazard ratio = 0.45 [0.27–0.78], P = 2.95 × 10−3, log-rank test, Fig. 2h), indicating that MIR200CHG could serve as a prognostic biomarker for GC. This evidence concerns the gene MIR200CHG and gastric cancer.